Calliditas Therapeutics AB -FDA Approval of TARPEYO to Reduce Proteinuria in IgA Nephropathy Transcript
Welcome to the Calliditas Therapeutics Audiocast Press Conference 2021.
(Operator Instructions)
I'll now hand the floor to CEO, Renee Aguiar-Lucander. Please begin your meeting.
()-
Thank you very much, and welcome to everybody joining us on this call. I'd just like to draw your attention to Page number 2. Yesterday, we issued a press release announcing FDA's accelerated approval of TARPEYO, which was known as Nefecon during its development.
But please note that certain information discussed on the call today is covered unders the safe harbor provision of the Private Securities Litigation Reform Act. During this call, management be making forward-looking statements.
Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated for the company's business. These forward-looking statements are qualified by the cautionary statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
